手术联合腔内支架置入治疗下肢动脉硬化性闭塞症

下肢动脉硬化症多由动脉粥样硬化、血栓闭塞性脉管炎、糖尿病等症引起。患者多为高龄,且多合并存在高血压、高脂血症,以及不同程度的冠状动脉粥样硬化,治疗较为棘手。我们1年来对6例8肢多节段硬化闭塞病患者行手术联合支架治疗,取得一定疗效。现报道如下。1材料和方法1.1一般资     

64层螺旋CT在糖尿病下肢动脉硬化闭塞症中的诊断价值

目的评价64层螺旋CT下肢动脉成像在诊断糖尿病下肢动脉硬化闭塞症中的临床价值。方法对90例可疑下肢血管病变的Ⅱ型糖尿病患者进行64层螺旋CT血管造影检查,对所有扫描原始数据行容积再现(VR),最大密度投影(M IP),冠状、矢状面多平面重组(MPR)以及曲面重建(CPR)。结果64层螺旋CT下肢血管造影检查可以清晰显示自髂总至足背整个动脉系统病变的准确部位、范围及侧枝血管。90例患者中67例(77%)患者血管呈不同程度粥样硬化表现。其中轻或中度狭窄49例(56.3%),重度狭窄18例(20.7%),7例(8%)完全闭塞患者可见侧枝循环血管形成。结论64层螺旋CT下肢血管造影,对糖尿病下肢动脉硬化闭塞症的诊断和治疗具有重要价值。     

Castleman病所致的与副肿瘤性天疱疮相关的闭塞性细支气管炎的临床病理与影像

目的 探讨与Castleman病所致的副肿瘤性天疱疮（PNP）相关的闭塞性细支气管炎（BO）的临床，病理与影像学特征。方法 5例患者包括男3例。女2例，平均年龄21岁。4例BO患者经临床诊断，1例经病理证实，所有患者均行吸气相和呼气相X线胸片和高分辨率CT（HRCT）扫描检查。结果 5例患者分别在PNP出现1-8个月后继发BO症状，胸片4例表现为双肺透亮度增加和血管纹理稀疏等过度充气改变，HRCT显示为弥漫性空气潴留征者5例。双肺多个亚段及其远端较大的细支气管柱状扩张4例。小叶核心和支气管管壁增厚4例。纵隔积气3例。片状肺泡实变（磨玻璃影）2例。术后随访5个月至3年均预后不良，呈现不同程度的Ⅱ型呼吸衰竭症状。结论 BO是伴有PNP的Castleman病的少见而严重的合并症，是导致预后不良的主要原因。HRCT上，BO的HRCT最常见表现包括呼气相空气潴留征，支气管扩张和小叶核心或支气管壁增厚。     

Effect of HMG CoA reductase inhibitors on the development of chronic lung allograft dysfunction

Lung transplant recipients (LRs) have a reduced median 5‐year survival of approximately 55% primarily due to chronic lung allograft dysfunction (CLAD). Statins have anti‐inflammatory and immunomodulatory effects that may facilitate CLAD prevention. This study sought to evaluate statin effect on CLAD development. Adult bilateral LRs from January 2004 to October 2013 were included. Statin group included recipients with early statin use and continued for minimum 6 months. Propensity score matching was performed for age, gender, and native lung disease to select matched nonstatin group. Competing risk approach was used to evaluate statin effect on CLAD development at 3 years while controlling for acute rejection and CMV pneumonitis. A total of 130 patients were included in each group. CLAD cumulative incidence at 3 years for statin and nonstatin groups was 20.6% (CI: 11.8%‐33.5%) and 22.4% (CI: 12.2%‐27.3%). Statin use was not associated with a decreased risk of CLAD (subdistribution hazard ratio [SHR]: 0.93, 95% CI: 0.55‐1.59, P = .80) but was associated with a decreased risk of death (SHR: 0.45, CI: 0.22‐0.90, P = .024). At 3 years, patient survival was 81.7% in statin group and 68.3% in nonstatin group (P = .012). Statins did not significantly delay the time to development of CLAD in LR but did demonstrate a benefit in patient survival.     

The histological diagnosis of clinically documented cases of cryptogenic organizing pneumonia: diagnostic features in transbronchial biopsies

Eleven cases of clinically diagnosed cryptogenic organizing pneumonia were examined in order to establish the histological features found at transbronchial biopsy and to correlate this with open lung biopsy which followed in six cases. The essential pathological feature was the presence of buds of granulation tissue (Masson bodies) indicating organization of a persistent exudate by fibroblasts and capillaries within alveoli, with preservation of the alveolar architecture. In addition, both acute and chronic inflammatory cells were present in the interstitium. These features, combined with the clinical history, were sufficient for a diagnosis in seven of the 11 cases on transbronchial biopsies. Four biopsies lacked these features. Patients proceeded to open lung biopsy in addition to the two with histological features of cryptogenic organizing pneumonia on transbronchial biopsy, but where the clinician wanted to eliminate other pathology because of rapid clinical deterioration. Five of the six cases coming to open lung biopsy confirmed cryptogenic organizing pneumonia with Masson bodies within alveoli, but changes were focal in three with very few Masson bodies in one. One case which had the features on transbronchial biopsy lacked them in the open lung biopsy. Transbronchial biopsy, therefore, can yield diagnostic material in the majority of patients with cryptogenic organizing pneumonia while open lung biopsy, which is considered the gold standard for interstitial lung disease, may yield negative results because of sampling error and the rapid evolution and changing pattern of the disease.     

腔内血管成形术治疗髂动脉长段慢性完全闭塞性病变

目的 评价腔内血管成形术治疗髂动脉长段慢性完全闭塞性病变(CTO)的可行性、有效性及安全性.方法 回顾性分析2006年1月至2010年12月经腔内血管成形术治疗的病变长度＞5 cm的髂动脉CTO患者139例(157条患肢)的临床资料.其中男性93例(105条患肢),女性46例(52条患肢);年龄50 ～96岁,平均年龄(77±10)岁.TASCⅡ分型:B型18例,C型89例,D型32例.采用左肱动脉和(或)股动脉穿刺经内膜下或血管内行髂动脉闭塞的球囊血管成形联合支架植入术治疗.结果 技术成功率96.2％ (151/157).踝肱指数由术前的0.42±0.19上升到术后的0.81±0.26.随访6～53个月,平均随访(30±7)个月,髂动脉支架畅通率94.1％ (111/118),7例发生支架内再狭窄或闭塞,无髂动脉破裂、支架移位、穿刺动脉假性动脉瘤及动静脉瘘的发生.结论 腔内血管成形术治疗髂动脉长段CTO安全、有效,术后支架通畅率高,联合肱动脉和股动脉双向穿刺技术能够显著提高技术成功率.     

Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a pilot study

Bronchiolitis obliterans syndrome (BOS) remains the major hurdle to improve long‐term survival after lung transplantation, as its treatment remains troublesome. In this pilot study, we investigated the effect of montelukast (a leukotriene receptor antagonist) on the FEV₁ decline after diagnosis of BOS and compared this with a control group. In both groups, 11 patients were included with BOS stage <3 and bronchoalveolar lavage (BAL) neutrophilia <15%, already being treated or concurrently being started on azithromycin. Control patients were selected retrospectively. After adding montelukast (10 mg/day) to the immunosuppressive regimen, the FEV₁ decline significantly decreased from 112 ± 26 ml/month before BOS diagnosis to 13 ± 13 ml/month after 6 months of montelukast therapy (P = 0.001). In the control group, there was no significant change in the rate of FEV₁ decline: 103 ± 20 ml/month before BOS diagnosis to 114 ± 27 ml/month (P = 0.55). Adding montelukast may be a promising treatment option in patients with low neutrophilic (<15%) BOS after lung transplantation, already or concurrently being treated with azithromycin.     

Multicenter evaluation of parametric response mapping as an indicator of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation

Parametric response mapping (PRM) is a novel computed tomography (CT) technology that has shown potential for assessment of bronchiolitis obliterans syndrome (BOS) after hematopoietic stem cell transplantation (HCT). The primary aim of this study was to evaluate whether variations in image acquisition under real‐world conditions affect the PRM measurements of clinically diagnosed BOS. CT scans were obtained retrospectively from 72 HCT recipients with BOS and graft‐versus‐host disease from Fred Hutchinson Cancer Research Center, Karolinska Institute, and the University of Michigan. Whole lung volumetric scans were performed at inspiration and expiration using site‐specific acquisition and reconstruction protocols. PRM and pulmonary function measurements were assessed. Patients with moderately severe BOS at diagnosis (median forced expiratory volume at 1 second [FEV1] 53.5% predicted) had similar characteristics between sites. Variations in site‐specific CT acquisition protocols had a negligible effect on the PRM‐derived small airways disease (SAD), that is, BOS measurements. PRM‐derived SAD was found to correlate with FEV1% predicted and FEV1/ forced vital capacity (R = ?0.236, P = .046; and R = ?0.689, P < .0001, respectively), which suggests that elevated levels in the PRM measurements are primarily affected by BOS airflow obstruction and not CT scan acquisition parameters. Based on these results, PRM may be applied broadly for post‐HCT diagnosis and monitoring of BOS.     

Lentivirus IL‐10 Gene Therapy Down‐Regulates IL‐17 and Attenuates Mouse Orthotopic Lung Allograft Rejection

The purpose of the study was to examine the effect of lentivirus‐mediated IL‐10 gene therapy to target lung allograft rejection in a mouse orthotopic left lung transplantation model. IL‐10 may regulate posttransplant immunity mediated by IL‐17. Lentivirus‐mediated trans‐airway luciferase gene transfer to the donor lung resulted in persistent luciferase activity up to 6 months posttransplant in the isograft (B6 to B6); luciferase activity decreased in minor‐mismatched allograft lungs (B10 to B6) in association with moderate rejection. Fully MHC‐mismatched allograft transplantation (BALB/c to B6) resulted in severe rejection and complete loss of luciferase activity. In minor‐mismatched allografts, IL‐10‐encoding lentivirus gene therapy reduced the acute rejection score compared with the lentivirus‐luciferase control at posttransplant day 28 (3.0 ± 0.6 vs. 2.0 ± 0.6 (mean ± SD); p = 0.025; n = 6/group). IL‐10 gene therapy also significantly reduced gene expression of IL‐17, IL‐23, and retinoic acid‐related orphan receptor (ROR)‐γt without affecting levels of IL‐12 and interferon‐γ (IFN‐γ). Cells expressing IL‐17 were dramatically reduced in the allograft lung. In conclusion, lentivirus‐mediated IL‐10 gene therapy significantly reduced expression of IL‐17 and other associated genes in the transplanted allograft lung and attenuated posttransplant immune responses after orthotopic lung transplantation.     

弹簧支架在下肢动脉硬化性狭窄和闭塞治疗中的应用

目的总结使用弹簧支架对下肢动脉硬化性狭窄和闭塞行介入球囊扩张、支架术的临床经验和近、远期疗效。方法对23例患者的29条肢体的下肢动脉硬化性病变行球囊扩张后置入弹簧支架（Introcoil）。结果成功完成29条肢体的治疗，无术中并发症。置入后即时造影示病变处管径明显增大，血流通畅。所有患者均获2～36个月随访，平均随访20个月。6例患者的6条肢体（20．7％）因重新出现动脉闭塞而行搭桥手术，其他患者下肢原有症状消失，20条足背动脉搏动恢复，超声示支架处血流通畅。结论弹簧支架置入是一种有效的下肢动脉狭窄和闭塞的介入治疗方法。